The primary aim of this exploratory, qualitative study was to understand the experience of individuals who have had the pathogenicity of a hereditary breast and ovarian cancer (BRCA1 or BRCA2) or Lynch syndrome (LS)-related (MLH1, MSH2, MSH6 or PMS2) gene variant reclassified, with a particular focus on those who have had a clinically significant change. This evidence concerns the gene MSH2 and Lynch syndrome.